Becton, Dickinson and Company
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Thomas E. Polen Jr.
- Full Time Employees
- 72,000
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Address
- 1 Becton Drive Franklin Lakes NJ United States of America 07417-1880
- IPO Date
- Feb 21, 1973
- CIK
- 0000010795
- Website
- bd.com
- Similar Companies
- Business
- Becton, Dickinson and Company (BDX) manufactures and distributes medical devices, instrument systems, and reagents worldwide. The company develops, produces, and sells a broad portfolio of products including syringes, catheters, infusion therapy devices, and diagnostic systems; safety-engineered sharps and vascular access products; BD Alaris infusion pumps and Pyxis medication management solutions; BD FACSAria flow cytometers and Rhapsody single-cell analysis platforms; and laboratory automation systems such as BD Kiestra and BD Synapsys informatics. BD operates in three main segments—BD Medical, BD Life Sciences, and BD Interventional—serving healthcare facilities, laboratories, pharmaceutical companies, and research institutions across North America, Europe, Asia-Pacific, and emerging markets. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD maintains a global presence with manufacturing facilities in more than 50 countries. In recent developments, BD completed the spin-off of its Biosciences solution business into a standalone entity in early 2025, enabling focused growth in high-margin diagnostics and cell analysis; the company also expanded its partnership with GE HealthCare for integrated medication management technologies and launched new Alaris iPC infusion pump features to enhance cybersecurity and interoperability.
Buy, Sell, or Hold These 4 Dividend Kings After Earnings: BDX, ED, EMR, PH
Becton Dickinson: An Earnings Beat Again As Diverse Clinical Portfolio Keeps On Growing
BDX DCF Analysis: Intrinsic Value $141 vs Price $181
BD Accelerates Advanced Tissue Regeneration Strategy with Landmark PREVENT Trial
First Eagle Investment Buys Becton Dickinson & Co (BDX) -- Shares Look 6% Undervalued on GF Value
We Said These 4 Dividend Aristocrats Could Soar. Here's How They Did, Plus 3 New Picks.
Becton Dickinson & Co (BDX) (Q3 2026) Earnings Call Highlights: Strong Revenue Growth and Raised Guidance Amid Tariff Pressures
Becton, Dickinson and Company Q3 Earnings Call Highlights
BD Stock Up in Pre-Market Post Q3 Earnings & Revenue Beat, Margins Down
Becton, Dickinson and Company (BDX) Q3 2026 Earnings Call Transcript
Becton Dickinson Signals Strong Growth Momentum By Raising Profit Outlook
Becton Dickinson (BDX) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
Becton Dickinson (BDX) Q3 Earnings and Revenues Surpass Estimates
BD Reports Third Quarter Fiscal 2026 Financial Results
Can Segment Strength Offset Headwinds for BD Stock Before Q3 Earnings?
Countdown to Becton Dickinson (BDX) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS
Becton Dickinson issues recall on certain lots of needle sets used for emergency IV access
3 Beaten-Down Stocks With GLP-1 Exposure to Buy and Hold
EMS and BD expand access to GLP-1 therapies in Brazil with semaglutide launch
BD Board Declares Dividend